IGF1 LR3 1mg
EACH VIAL CONTAINS 1MG OF IGF1 LR3
Supplied for Research Purposes Only
This information and product is provided for research purposes only. We do not provide any advice on the usage of these products as UK Law prevents this. Customers should check the legality of this product in their own country prior to purchase.
Benefits and uses:
A rise in the percentage of lean muscle mass.
Enhancement of performance in athletic competition.
An increase in hyperbolas in the muscle cells, which ultimately results in fuller muscle tissues.
Enhancement of muscle recovery and reduction in the amount of time required to recover.
Lowering of total body fat percentage.
An increase in metabolism.
Control of the storage of fat and the prompting of fat to be used for the production of energy.
Contribution to the body's process of protein synthesis facilitation.
Augmentation of the protective effects of antioxidants and the tensile capacity of ligaments.
50mcg daily (male), 20mcg daily (female) for up to 4 weeks with a 2 week break.
What is IGF-1 LR3
IGF-1, also known as somatomedin C, has quickly gained popularity and been the subject of much discussion from the middle of the 2000s until the present year of 2017. IGF-1 is thought to have been used for the first time by Mr. Olympia Dorian Yates in the early 1990s. At the time, it was a rumoured to be a very difficult and expensive substance to obtain, and after that, its use swiftly spread among other professional bodybuilders.
IGF-1 is a protein hormone (sometimes referred to as a polypeptide or simply a peptide hormone), not an anabolic steroid, and it shares many structural similarities with insulin, another peptide/protein hormone. The human body spontaneously produces and synthesises IGF-1 endogenously, mostly in the liver. Human Growth Hormone stimulates and initiates the liver's production of IGF-1 (HGH). Essentially, HGH functions as a prohormone for IGF-1, and the majority of its anabolic benefits come from IGF-1's subsequent synthesis.
Although IGF-1 (also known as insulin-like growth factor 1) and insulin have many similarities, they serve slightly different functions. IGF-1, like insulin, is a hormone that stimulates the movement of nutrients into muscle cells, including glucose and amino acids. These nutrients can subsequently be utilised by the cells to build new muscular tissue. Intestinal, connective, and bone tissues all exhibit anabolic properties of IGF-1. This is different from insulin, which in a larger meaning of the word is a hormone that transports nutrients to many different tissues throughout the body in addition to muscle tissue. In other words, compared to IGF-1, insulin is not as selective of a hormone that shuttles.
The human body uses IGF-1 for a variety of distinct and precise functions, and these functions change as a person develops. For instance, it is in charge of several crucial aspects of a child's growth and also manifests anabolic effects in adults. IGF-1 is largely used in medicine to treat growth failure, although as it was only recently discovered, the disorders for which it has been tested are constantly expanding. Its clinical research and medical applications cover diseases like dwarfism, ageing, neuropathy, cancer, and even stroke.
Recently, numerous IGF-1 variations have been created for use, including IGF-1, IGF-1 LR3, and IGF-1 DES, each with unique qualities in terms of half-life and application. First-time potential users may find these bewildering, especially given the abundance of confusing information available online, but this will be covered in more detail later in this article.
Chemical Composition and Properties of IGF-1
A polypeptide hormone called IGF-1 has a chain of 70 amino acids. In contrast, insulin contains 51 amino acids total. It is a very anabolic hormone that, as was already established, is very specific to muscle tissue and shuttles nutrients. Additionally, it is anabolic to intestinal tissues, connective tissue, and bone. The truth is that, as was already mentioned, HGH stimulates the production of endogenous and naturally occurring IGF-1, effectively acting as a releaser of IGF-1. As a result, the effects of increased HGH dosage are constrained by the maximum amount of IGF-1 that the liver can produce at any given time. The benefits of using exogenous IGF-1 in this situation come into play. In addition to being a hormone that shuttles nutrients, IGF-1 also encourages muscle cell hyperplasia, which is the expansion and creation of new muscle cells as opposed to muscle cell hypertrophy (which is the growth of existing muscle cells in size).
However, there are a few crucial distinctions that must be made in order to fully comprehend IGF-1's function. The first is that, according to studies, 99 percent of the IGF-1 circulating in the bloodstream is bound to a few specific binding proteins, whereas free (or, un-bound) IGF-1 is what stimulates the proliferation of muscle cells (hyperplasia). As a result, IGF-1 structural modification techniques have been developed by the pharmaceutical industry to solve or prevent the issue of IGF-1 molecules binding to binding proteins. The outcomes are, of course, the various IGF-1 varieties that have been created for use.
The second distinction is that IGF-1 always acts systemically in the body, regardless of the variant or type in question. This means that after being administered, it circulates throughout the entire body, affects all muscle tissue, and has no localised growth-promoting effects.
Types of IGF-1 (IGF-1 LR3, IGF-1 DES)
IGF-1 is primarily accessible in 2 different formats or variations, as was already explained. It's crucial to keep in mind that all variants have a systemic effect on the body and that, despite being administered intramuscularly into a specific muscle, none of them will result in detectable localised growth that would justify doing so.
IGF-1 LR3: This is listed first since it is the most widely available and well-liked IGF-1 variation on the market and is being used by bodybuilders and sportsmen. It contains bio-identical IGF-1 plus an extra 13 amino acids at the end of the original 70-amino acid chain, making a total of 83 amino acids. In a second change, the original glutamic acid at position three has been replaced with an arginine. These changes have the effect of maintaining the IGF-1's original activity at the IGF-1 receptor in bodily tissues while greatly decreasing its affinity for the previously stated IGF binding proteins. In addition, it has a half-life that is considerably longer than IGF-1's, at around 20 to 30 hours as opposed to 12 to 15 hours. Together, these elements have shown that LR3 has nearly three times the efficacy of IGF-1.
Side Effects of IGF-1
Studies, medical literature, and user feedback indicate that IGF-1's adverse effect profile and most people's tolerance to it are generally widely accepted. This is particularly true for bodybuilders and sportsmen who have used it. IGF-1 does, however, have certain possible hazards and negative effects, just like everything else. The bulk of IGF-1 adverse effects are primarily long-term negative effects and dangers, which are typically brought on by prolonged use (and of course, dosage).
Short-term hypoglycemia (low blood glucose levels) is a side effect of IGF-1 that can occur due to the hormone's function as a hormone that shuttles and partitions nutrients, as was discussed before in this article. The risk of rapidly dropping blood plasma glucose levels exists because IGF-1 rapidly enhances the absorption of glucose into muscle cells (and other cell types as well). Despite the fact that it happens at rates far lower than those of insulin, this is still a possible risk and adverse effect. IGF-1 users who have diabetes or are at risk for developing the disease should exercise caution. IGF-1 users should be careful to monitor their blood glucose levels and signs and symptoms of hypoglycemia and change their diets accordingly, whether or not they have a history of diabetes.
IGF-1 can accelerate the growth of tumours and cancer in those who have already been diagnosed with active tumours and/or cancer or who may have a history of cancer because it is a growth factor and a growth hormone in and of itself. IGF-1 does not cause cancer, and this is crucial to comprehend. It is a very significant hormone that, among many other things, is crucial for the healthy operation of our heart, nervous system, and brain. Having said that, persons who have a history of cancer or who have been identified as having active malignancy.
Another IGF-1 side effect that is frequently mentioned is acromegaly, which is the enlargement of internal organs and intestinal tissue. This typically results from prolonged, heavy use and/or inappropriately high dosages. The excessive growth of bone tissue known as acromegaly typically shows up in the jaw and other extremities like the hands and feet. Long periods of unbroken use and significant dosages are necessary for this to happen. No IGF-1 cycle, notably IGF-1 LR3, should be used for more than 30 days at a time without taking a significant vacation from the drug. IGF-1 receptor sites on muscle tissue become saturated as treatment duration and/or hormone dosages increase, allowing any extra IGF-1 in the bloodstream to bind to other tissues (bone, internal organs, and intestinal tissue) and stimulate the growth of those tissues. With high doses and prolonged use, one can understand over time why and how this can develop into a problem (often irreversible).
IGF-1 LR3 dosages for administration, use, and dosage are as follows: Men shouldn't take more than 40 to 50 mcg per day, and women shouldn't use more than 20 mcg. The LR3 version should not be supplied more than twice per day due to its prolonged active half-life in the body. IGF-1 dosages on training/exercise days should be given either right before or right after the session. The choice is up to the user, as either before or after is acceptable (as is pre-workout only, or post-workout only). The whole daily dosage can be divided in half between the two doses if given twice daily (e.g. 20mcg pre-workout, and 20mcg post-workout for a total of 40mcg per day). It may be administered at any time of day on days when there is no training.
IGF-1 can be given intramuscularly or subcutaneously in either form. Before taking a break of at least two weeks between IGF-1 cycles, use of either form should not be continued for longer than a total of 30 days per cycle. However, longer intervals beyond two weeks are advised. This is done in order to prevent long-term health impacts and to guarantee that IGF-1 receptors function normally after a cycle.
Both IGF-1 variations are supplied as lyophilized powders, which are dehydrated/dried out powders that must be reconstituted with either bacteriostatic water or, more frequently in the case of LR3, a small amount of acetic acid diluted into bacteriostatic water. The user is responsible for determining how much water needs to be added to the lyophilized powder in order to properly rehydrate it and create the required concentration. The majority of IGF-1 preparations (including LR3 and DES versions) typically contain 1 mg of lyophilized powder in total. The user will receive 50mcg every 10iu (or 0.10ml) of water if 2ml of bacteriostatic water is added to the powder. Depending on the product purchased and how the user desires to rehydrate the product with any desired amount of water, concentrations can and will vary. Before reconstituting, it is essential that anyone who wants to utilise any kind of IGF-1 is aware of the correct fundamental mathematical computations.
IGF-1 is now only available as research peptides that are marketed by several research chemical manufacturing companies. They may be legitimately acquired from a variety of research firms or from their websites. These goods are solely meant for study and laboratory use; they are not meant for human use or consumption unless they are applied in a research and clinical context that has received FDA and medical establishments/organizations' approval and sanction. They are not a pharmaceutical-grade item, a medical item, or something that is meant for human usage. As a result, quality assurance procedures and production standards will be similar.
Tomas FM, Lemmey AB, Read LC, Ballard FJ (1996). "Superior potency of infused IGF-I analogues which bind poorly to IGF-binding proteins is maintained when administered by injection". J. Endocrinol. 150 (1): 77–84. doi:10.1677/joe.0.1500077. PMID 8708565.
Mohan S, Baylink DJ (2002). "IGF-binding proteins are multifunctional and act via IGF-dependent and -independent mechanisms". J. Endocrinol. 175 (1): 19–31. doi:10.1677/joe.0.1750019. PMID 12379487.
Tomas FM, Knowles SE, Owens PC, Chandler CS, Francis GL, Read LC, Ballard FJ (1992). "Insulin-like growth factor-I (IGF-I) and especially IGF-I variants are anabolic in dexamethasone-treated rats". Biochem. J. 282 ( Pt 1): 91–7. doi:10.1042/bj2820091. PMC 1130894. PMID 1371669.
von der Thüsen JH, Borensztajn KS, Moimas S, van Heiningen S, Teeling P, van Berkel TJ, Biessen EA (2011). "IGF-1 has plaque-stabilizing effects in atherosclerosis by altering vascular smooth muscle cell phenotype". Am. J. Pathol. 178 (2): 924–34. doi:10.1016/j.ajpath.2010.10.007. PMC 3069834. PMID 21281823.
Mario Thevis (13 December 2010). Mass Spectrometry in Sports Drug Testing: Characterization of Prohibited Substances and Doping Control Analytical Assays. John Wiley & Sons. pp. 252–. ISBN 978-1-118-03514-6.